ARCHIVES

Dendreon Claims “Clear Hit” On Provenge, But Skeptics Await Data Presentation

This article is from The Cancer Letter archive.

Vol. 35 No. 15 | April 17, 2009

Download PDF Visit The Full Archive

Related Articles

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

October 17, 2014

Regions Outlined In CIS Proposal

May 31, 1991

NCI Programs: BSA Approves Formation Of Two Grant Programs:

July 2, 1999

Concept Approval Given To $7 Million In OD Recompetitions, Renewals

May 28, 1982

Rituximab Maintenance Improves Survival In Relapse

February 27, 2009

In Brief: Breast Cancer Detection Concept Was For Grants, Not Contracts; Wallens Gets Five Years Probation

November 16, 1984